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Abstract
Background:  Liver X receptor alpha (LXRA) and beta (LXRB) regulate glucose and lipid
homeostasis in model systems but their importance in human physiology is poorly understood. This
project aimed to determine whether common genetic variations in LXRA and LXRB associate with
type 2 diabetes (T2D) and quantitative measures of glucose homeostasis, and, if so, reveal the
underlying mechanisms.
Methods: Eight common single nucleotide polymorphisms in LXRA and LXRB were analyzed for
association with T2D in one French cohort (N = 988 cases and 941 controls), and for association
with quantitative measures reflecting glucose homeostasis in two non-diabetic population-based
samples comprising N = 697 and N = 1344 adults. Investigated quantitative phenotypes included
fasting plasma glucose, serum insulin, and HOMAIR as measure of overall insulin resistance. An oral
glucose tolerance test was performed in N = 1344 of adults. The two alleles of the proximal LXRB
promoter, differing only at the SNP rs17373080, were cloned into reporter vectors and transiently
transfected, whereupon allele-specific luciferase activity was measured. rs17373080 overlapped,
according to in silico analysis, with a binding site for Nuclear factor 1 (NF1). Promoter alleles were
tested for interaction with NF1 using direct DNA binding and transactivation assays.
Results:  Genotypes at two LXRB  promoter SNPs, rs35463555 and rs17373080, associated
nominally with T2D (P values 0.047 and 0.026). No LXRA or LXRB SNP associated with quantitative
measures reflecting glucose homeostasis. The rs17373080 C allele displayed higher basal
transcription activity (P value < 0.05). The DNA-mobility shift assay indicated that oligonucleotides
corresponding to either rs17373080 allele bound NF1 transcription factors in whole cell extracts
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to the same extent. Different NF1 family members showed different capacity to transactivate the
LXRB gene promoter, but there was no difference between promoter alleles in NF1 induced
transactivation activity.
Conclusion: Variations in the LXRB gene promoter may be part of the aetiology of T2D. However,
the association between LXRB rs35463555 and rs17373080, and T2D are preliminary and needs to
be investigated in additional larger cohorts. Common genetic variation in LXRA is unlikely to affect
the risk of developing T2D or quantitative phenotypes related to glucose homeostasis.
Background
Type 2 diabetes (T2D) is a common cause of morbidity
and mortality and is caused by a western sedentary life
style with high calory diet in combination with suscepti-
bility genes. Without life style changes, available pharma-
ceutical treatments of T2D are only partially efficient.
Recently, large scale allelic association analyses have
begun to identify the genetic factors underlying suscepti-
bility to T2D [1]. This new knowledge may permit unrav-
elling of pathways leading to development of T2D and
thereby aid in the development of more efficient preven-
tion and therapy of this disease.
Liver X receptor alpha (LXRA, NR1H3) and beta (LXRB,
NR1H2) are established sensors of lipid and cholesterol
homeostasis [2]. Recently, a large body of literature has
indicated a role of LXRs also in glucose metabolism and
homeostasis. Several studies have demonstrated that LXR
agonists reduce plasma glucose concentrations and
increase insulin sensitivity in different models of diabetes
and insulin resistance [3,4]. LXRs seem to improve glu-
cose metabolism at different levels. In experimental mod-
els, LXR activation inhibits hepatic gluconeogenesis and
glucose output [5,6]. Other results support that LXRs reg-
ulate peripheral glucose uptake. Activation of LXRs pro-
motes glucose uptake and oxidation in muscle, and
expression of the insulin responsive glucose transporter
Glucose transporter type 4 (GLUT4) in adipocytes [5,7,8].
LXRs are also implicated in regulation of insulin secretion.
Activation of LXRs increases glucose dependent insulin
secretion in vitro from pancreatic beta-cell line cultures
[9]. This effect may be mediated through LXRB since Lxrb-
/- mice have lower basal insulin levels and are glucose
intolerant due to impaired glucose induced insulin secre-
tion [10]. Together, these observations point towards a
physiological role of LXRs in glucose homeostasis.
We have previously reported that two LXRB SNPs associ-
ate with obesity in a Swedish cohort [rs35463555 (previ-
ously known as LB44732G>A), rs2695121, and
marginally, rs17373080 (P value 0.06)] [11]. Further-
more, one LXRA SNP (rs11039155) was reported to asso-
ciate with the metabolic syndrome in two French cohorts
[12]. LXRA is encoded on human chromosome 11p11.2
and LXRB on chromosome 19q13.3.
Here we analyze if eight common SNPs in LXRA and LXRB
associate with T2D in one French case-control cohort, and
to phenotypes related to glucose homeostasis in two non-
diabetic population-based cohorts comprising adult
French and Swedish subjects. We also investigate the
impact of one LXRB promoter SNP on gene transcription
in vitro.
Methods
Subjects
The present study includes one large French cohort that
was used for analysis of association between LXR gene
SNPs and T2D. In addition, a subset of the non-diabetics
in the French cohort, that is D.E.S.I.R., as well as the non-
diabetics in the Swedish Stockholm Diabetes Prevention
Program (SDPP) cohort, were analyzed for association
between LXR SNPs and quantitative phenotypes related to
glucose homeostasis. The cohorts used for quantitative
trait analyses were population based. The study was
approved by the ethical committee of the Karolinska Uni-
versity Hospital, the French National Commission for
Informatics and Liberty and Hotel Dieu Ethics Commit-
tee. Informed written consent was received from all partic-
ipants.
French cohort
The French T2D group included 988 unrelated T2D
patients (N = 662 males and 326 females, age at examina-
tion 61.0 ± 10.2 years, BMI 26.3 ± 2.5 kg/m2) recruited at
the Endocrinology-Diabetology Department of the Cor-
beil-Essonnes Hospital [13]. The type 2 diabetes status
was defined according to the World Health Organization
1999 criteria [14]. The T2D patients included in the study
were selected on a BMI < 30 kg/m2 and all were unrelated.
346 T2D subjects were treated with insulin, 624 were
treated with oral anti-diabetic drugs, and 18 subjects had
other anti-diabetic treatment. The 941 control subjects
were selected on fasting plasma glucose < 6.1 mmol/l and
BMI < 27 kg/m2 (N = 380 males and 561 females, age at
examination 62.2.0 ± 7.5 years, BMI 23.2 ± 2.0 kg/m2)
and all were unrelated. Of the 941 controls, 697 were
selected from the D.E.S.I.R. general French population
[15] and 244 were selected from the French families
recruited at the CNRS unit in Lille. All subjects are of
French Caucasian origin. We have compared the geno-BMC Medical Genetics 2009, 10:27 http://www.biomedcentral.com/1471-2350/10/27
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Schematic figure of LXRA and LXRB genes with position of genotyped SNPs according to NCBI as indicated Figure 1
Schematic figure of LXRA and LXRB genes with position of genotyped SNPs according to NCBI as indicated.BMC Medical Genetics 2009, 10:27 http://www.biomedcentral.com/1471-2350/10/27
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typic distributions within the control group depending on
the original selections. No significant difference was
observed. For 1021 subjects (case and controls) of this
study we could estimate the proportion of European
ancestry from a previous genome-wide genotyping [16].
We performed logistic regression taking into account also
the gender of the individuals, and observed at least 90%
(in 1005 subjects) or 99% (in 835 subjects) of European
ancestry (results below not included in the text). Thus, we
can potentially exclude a possible stratification in the
French study sample. Moreover, these results are sup-
ported by several other association studies [16-24]. Infor-
mation about family history of T2D was available for the
French family cohort and for most of the subjects that
were included as controls there was no T2D in the ances-
try. Family history of T2D was not available from the
D.E.S.I.R. participants. The size of the French cohort pro-
vided 70% (90%) power to detect an allele with a fre-
quency of 20% among controls and odds ratio (OR) 1.25
(1.35) to develop T2D assuming a threshold P value of
0.05 and dominant mode of inheritance (QUANTO,
http://hydra.usc.edu/gxe/) [25].
Table 1: Analysis of association between LXR alleles and T2D in French cases vs control
SNP Call HWE
Name Position Allelea #11b #12 #22 %1c %2 rate % P valued O.R. ± C.I.e
LXRA
rs4752822 5' T>C NDg 522 332 53 76 24 96 0.93 1.04 [0.89–1.21]
T2Dg 537 360 57 75 25
rs61896015 intron 2 C>A ND 711 180 16 88 12 97 0.79 1.13 [0.93–1.37]
T2D 729 221 15 87 13
rs12221497 intron 2 G>A ND 718 180 17 88 12 97 0.69 1.09 [0.90–1.33]
T2D 727 216 13 87 13
rs2279239 intron 4 T>C ND 518 328 52 76 24 97 0.94 1.03 [0.89–1.20]
T2D 549 355 60 75 25
rs2279238 exon 5 C>T ND 715 195 12 88 12 98 0.62 0.99 [0.81–1.2]
T2D 754 192 17 88 12
LXRB
rs35463555 promoter G>A ND 417 388 106 67 33 96 0.74 0.94 [0.82–1.08]
(-2046) T2D 433 432 84 68 32
rs17373080 promoter C>G ND 411 386 104 67 33 96 0.42 0.94 [0.82–1.08]
(-202) T2D 430 438 80 68 32
rs2248949 intron 6 C>T ND 310 432 139 60 40 93 0.05 1.02 [0.90–1.17]
T2D 303 476 136 59 41
a) Common allele is written first. b) #11 = number of subjects homozygous for common allele, #12 = number of heterozygous subjects, #22 = 
number of subjects homozygous for rare allele. c) Major allele frequency. d) HWE P values were calculated in HAPLOVIEW [32]. e) O.R. ± C.I. = 
odds ratio ± confidence intervals. ORs were calculated as (number allele 2 among cases * number allele 1 among controls)/(number allele 1 among 
cases * number allele 2 among controls). f) Pearson's Chi2 (d.f. = 1) was used to compare allele frequencies between T2D-cases and controls. g) ND 
= non-diabetic controls, T2D = type 2 diabeteBMC Medical Genetics 2009, 10:27 http://www.biomedcentral.com/1471-2350/10/27
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Swedish cohort
For the Swedish SDPP study, a short questionnaire was
sent to all men born between 1938 and 1957 living in
four municipalities in the outskirts of Stockholm and all
women born between 1942 and 1961 living in the same
municipalities and one additional municipality, asking
about country of birth and presence of diabetes in subjects
and relatives. Persons were excluded as a result of diabetes
and foreign origin. In a second step, subjects with family
history of diabetes, together with subjects randomly
selected from those without family history of diabetes,
matched to the first group by age and municipality were
invited to a health examination. Subjects with DNA avail-
able were included in this study.
SDPP included 1024 normoglycemic controls with nor-
mal glucose tolerance (N = 778 males and 246 females,
age at examination 46.7 ± 4.9 years, BMI 25.5 ± 4.4 kg/
m2) and 320 subjects with impaired glucose tolerance
(IGT) (N = 174 males and 146 females, age at examina-
tion 48.2 ± 4.5 years, BMI 29.2 ± 5.3 kg/m2) [26-29].
The size of the population-based non-diabetic Swedish
SDPP and French D.E.S.I.R. cohorts together provided
53% (98%) power to detect an allele with a frequency of
15% and marginal βG 0.2 (0.4) for HOMAIR as measure of
insulin resistance, assuming a threshold P value of 0.05
and dominant mode of inheritance (QUANTO, http://
hydra.usc.edu/gxe/) [25].
Clinical evaluation
In the morning a fasting venous blood sample was
obtained for determination of fasting levels of insulin and
glucose by the routine chemistry laboratory of the hospi-
tals, and for extraction of DNA using standard protocols.
An oral glucose tolerance test was performed in the SDPP
subjects. Diabetes was defined according to the World
Health Organization 1999 criteria: fasting plasma glucose
Linkage disequilibrium between LXRA and LXRB SNPs as indi- cated Figure 2
Linkage disequilibrium between LXRA and LXRB 
SNPs as indicated. Shown are r2 values. D' was 1.00 
between all SNPs within each gene.
LXRA LXRB LXRA LXRB
Table 2: Association of LXRB promoter SNP genotypes with T2D in the French cohort
Recessive Dominant
O.R.+C.I.
[22]<->[11]
P value O.R.+C.I.
[22]<->[11+12]
P value
rs35463555 1.310 [0.955–1.798] 0.09 1.356 [1.003–1.834] 0.047
rs17373080 1.360 [0.986–1.875] 0.06 1.416 [1.042–1.924] 0.026
1 = common allele, 2 = rare allele
OR: homozygous/recessive: (Case_11*Control_22)/(Case_22*Control_11), allele positivity/dominant: ((Case_12+Case_11)*Control_22)/
(Case_22*(Control_12+Control_11))
Table 3: Analysis of LXR haplotypes in T2D in the French cohort
Block Specific haplotype (%) nominal
Case Controls P Value
LXRA: rs4752822- rs61896015- rs12221497- rs2279239- rs2279238
TCGTC 75.1 75.9 0.56
CAACC 13.1 12.0 0.32
CCGCT 11.8 12.1 0.80
LXRB: rs35463555- rs17373080- rs2248949
GCT 41.0 40.6 0.81
AGC 31.7 33.0 0.41
GCC 27.2 26.4 0.55
Haplotype frequencies in cases versus controls are compared by Chi2 
test. Counts for association tests are obtained by summing the 
fractional likelihoods of each individual for each haplotype.BMC Medical Genetics 2009, 10:27 http://www.biomedcentral.com/1471-2350/10/27
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≥ 7.0 mmol/l and/or 2-h plasma glucose ≥ 11.1 mmol/l,
or ongoing treatment with oral antidiabetic agents and/or
insulin [14]. IGT was defined as fasting plasma glucose <
7.0 mmol/l and 2-h plasma glucose 7.8–11.0 mmol/l.
Insulin resistance index HOMAIR  (homeostasis model
assessment) was calculated as fasting serum insulin (μU/
ml) × fasting plasma glucose (mmol/l)/22.5 [30]. The
diagnosis of T2D as opposed to type 1 diabetes was based
on clinical records and judgment by the investigating phy-
sicians.
SNP selection and genotyping
We genotyped altogether five SNPs in the LXRA gene (Fig-
ure 1A). Three of the genotyped LXRA  SNPs cover the
common variation in this gene in a French cohort accord-
ing to Legry et al [12]. According to Legry et al a, LXRA
comprises three common haplotypes, which are tagged by
SNPs genotyped in the present study. We were unable to
design a multiplex assay including the SNP rs11039155,
which in French cohorts has been associated with the met-
abolic syndrome. However, we genotyped instead
rs2279238 that is in complete linkage disequilibrium
(LD) with rs11039155 [12]. Since the SNPs genotyped by
Legry did not fully cover the two untranslated 5' exons of
LXRA we added two more SNPs in this region from our
previous study of LXRA in obesity, that is rs4752822 and
rs61896015 (the latter previously labelled LA9462C>A)
[11]. For LXRB, we genotyped three SNPs that covered
57% of alleles as r2 ≥ 0.80 according to our own sequenc-
ing and genotyping of the gene in a Swedish cohort (Fig-
ure 1B) [11]. The reason for the relatively low coverage
was that we were unable to design a high throughput gen-
otyping assay for two variations; a repeat and a SNP
located in this repeat. The three SNPs cover the three com-
mon LXRB gene haplotypes according to our own previ-
ous genotyping of this gene in a Swedish cohort [11].
Table 4: Phenotypic distribution of cohorts
French T2D cases
all females males
number 988 326 662
Age (year) 61.0 ± 10.2 62.8 ± 10.7 60.1 ± 9.9
BMI (kg/m2) 26.3 ± 2.5 26.0 ± 2.8 26.4 ± 2.3
fP-Glucose (mmol/l) NA NA NA
fS-Insulin (pmol/l) NA NA NA
HOMAIR NA NA NA
French Normoglycemic controls
D.E.S.I.R. From the CNRS unit in Lille
all females males all females males
number 697 419 278 244 142 102
Age (year) 53.4 ± 5.6 53.2 ± 5.7 53.8 ± 5.6 60.9 ± 10.5 61.2 ± 10.9 60.6 ± 10.0
BMI (kg/m2) 23.2 ± 1.8 22.8 ± 1.7 23.9 ± 1.7 23.0 ± 2.8 22.4 ± 3.1 23.7 ± 2.0
fP-Glucose (mmol/l) 5.1 ± 0.4 5.0 ± 0.4 5.2 ± 0.3 5.0 ± 0.4 5.0 ± 0.4 5.2 ± 0.4
fS-Insulin (pmol/l) 5.1 ± 3.7 4.9 ± 2.3 5.3 ± 5.2 7.4 ± 5.2 7.1 ± 4.6 7.7 ± 5.9
HOMAIR 1.3 ± 0.6 1.3 ± 0.6 1.4 ± 0.7 1.7 ± 1.2 1.6 ± 1.0 1.8 ± 1.4
Swedish SDPP
Normoglycemic controls Impaired glucose tolerance
number 1024 246 778 320 146 174
Age (year) 46.7 ± 4.9 47.0 ± 4.6 46.6 ± 5.0 48.2 ± 4.5 48.6 ± 4.4 48.0 ± 4.6
BMI (kg/m2) 25.5 ± 4.4 22.6 ± 1.7 26.5 ± 4.5 29.2 ± 5.3 29.2 ± 6.0 29.2 ± 4.6
fP-Glucose (mmol/l) 4.6 ± 0.5 4.5 ± 0.4 4.7 ± 0.6 5.3 ± 0.7 5.2 ± 0.6 5.5 ± 0.7
fS-Insulin (pmol/l) 18.0 ± 10.2 9.2 ± 3.6 20.7 ± 10.0 22.0 ± 11.8 15.6 ± 7.6 27.1 ± 12.1
HOMAIR 3.7 ± 2.3 1.8 ± 0.8 4.3 ± 2.3 5.2 ± 3.2 3.5 ± 2.1 6.6 ± 3.2
2 h P-Glucose (mmol/l) 4.5 ± 1.2 4.1 ± 1.0 4.7 ± 1.3 8.7 ± 1.0 8.8 ± 0.8 8.7 ± 1.1
Values are mean ± SD. NA = not availableBMC Medical Genetics 2009, 10:27 http://www.biomedcentral.com/1471-2350/10/27
Page 7 of 13
(page number not for citation purposes)
Both samples were genotyped using matrix-assisted laser
desorption/ionization time-of-flight (MALDI-TOF) mass
spectrometry [31]. Primers are provided on request. Due
to initial low call rate, rs2248949 was re-genotyped by
Taqman in a subset of the Swedish cohort
(C_1993248_20, Applied Biosystems, Foster City, CA,
USA). The final genotype call rate was ≥ 93% for all SNPs.
The accuracy was 99.99% according to duplicate analysis
of, on average, 2% of the total genotypes. Hardy-Wein-
berg equilibrium (HWE) calculations were performed in
Haploview to ensure that each marker was within popula-
tion equilibrium [32].
Cloning of the LXRB promoter into reporter vectors and 
in vitro mutagenesis
The -244/+1163 sequence of the human LXRB gene was
cloned into the pGL3 basic luciferase reporter vector
(Promega) using the Kpn I and Mlu I sites applying prim-
ers 5'-ATCAGGTACCGGCCGCAGGCTCAGAGAAGCG-
CATGAATGAGCTAA-3' and 5'-AT CAC TCGAGG GTG
GGGTCACGGAGCAGCCTGTAGAATACAGGGGATTGA-
GAG-3' with the restriction enzyme sites underlined. The
G allele (bold) of rs17373080 was generated using the fol-
lowing primer (5'-TAAAGCCAGAAAGCGCGGGGCT-
GGAGGTTT-3' using the QuikChange® XL Site-Directed
Mutagenesis Kit (Stratagene). DNA sequencing confirmed
the identity of all clones.
Transient transfections
The mouse pancreatic beta-cell line MIN6 was maintained
in Dulbecco's modified Eagle's medium (DMEM, 4.5 g/L
glucose, 41965-039), the human hepatoma cell line
HuH7 was grown in DMEM with 0.11 G/L NaPyr (41966-
029), and African green monkey kidney cells Cos7 in
DMEM with 1 g/L glucose (31885-023). All media were
from GIBCO-BRL. The cell lines were supplemented with
fetal bovine serum (Cos7, HuH7: 10%, MIN6: 15%), 2
mM L-glutamine (only MIN6), and penicillin/streptomy-
cin at a final concentration of 100 U/ml and 100 μg/ml,
respectively. Additionally, 50 μM β-mercaptoethanol was
added to the MIN6 cells. Cells were grown under 5% CO2
at 37°C. Approximately 4 × 104 cells per well were plated
in 24 well plates and transiently transfected using Lipo-
fectamine 2000 (Invitrogen, Carlsbad, CA) according to
the manufacturer's protocol. Each well received 50 ng of
reporter vector and 125 ng of expression vector, respec-
tively. Vehicle vector was added to ensure equal amounts
of DNA in each transfection. Cells were transfected for 24
h and thereafter lysed in 25 mM TAE, 1 mM EDTA, 10%
glycerol, 1% Triton X-100, and 2 mM DTT. Luciferase
activities were measured using a Luciferase Assay Kit
(BioThema, Umeå, Sweden) in a luminometer (Luminos-
can Ascent, Thermo electron Corporation, Waltham, MA).
The NF1 transcription factors were cloned into the pCH-
expression vectors and were a kind gift of Dr. Gronosta-
jski, Cleveland Clinic Foundation Research Institute.
Table 5: LXR genotypes in the Swedish population based SDPP cohort
SNP Allelea #11b #12 #22 %11 %12 %22 %1c %2 call rate % HWE
P valued
LXRA
rs4752822 T>C 570 605 157 43 45 12 66 34 99 0.91
rs61896015 C>A 886 377 47 68 29 4 82 18 97 0.42
rs12221497 G>A 902 370 47 68 28 4 82 18 98 0.27
rs2279239 T>C 559 590 151 43 45 12 66 34 97 0.86
rs2279238 C>T 923 360 35 70 27 3 84 16 98 1.00
LXRB
rs35463555 G>A 612 576 140 46 43 11 68 32 99 0.86
rs17373080 C>G 613 578 137 46 43 11 68 32 99 1.00
rs2248949 C>T 426 607 267 33 47 20 56 44 97 0.07
a) Common allele is written first. b) #11 = number of subjects homozygous for common allele, #12 = number of heterozygous subjects, #22 = 
number of subjects homozygous for rare allele. c) Major allele frequency. d) HWE P values were calculated in HAPLOVIEW [32].BMC Medical Genetics 2009, 10:27 http://www.biomedcentral.com/1471-2350/10/27
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Whole cell extracts
MIN6 cells were grown to confluence in 100 mm dishes,
washed with PBS and incubated in TEN buffer (40 mM
Tris-HCl, 1 mM EDTA, 150 mM NaCl) for 4 min. Cells
were then removed with a cell scraper and pelleted by cen-
trifugation at 3,500 rpm for 2 min at 4°C. Cell pellets
were freeze dried on dry ice and resuspended in 50 μl ice-
cold buffer C (10 mM Hepes-KOH pH 7.9, 0.4 M NaCl,
0.1 mM EDTA, 5% glycerol, 1 mM DTT, 0.5 mM PMSF).
After another round of freeze drying, cell debris were
removed by centrifugation for 5 min at 13,000 rpm at
4°C. The supernatant corresponds to MIN6 whole cell
extracts.
Electro mobility shift assay (EMSA)
The oligo including a consensus site for nuclear factor 1
(NF1) is 5'-GATCTTATTTTGGATTGAAGCCAATATGAG-
3'. The rs17373080 C allele oligo is 5'-GC TAAAG
CCACAAAGCGCGGGG-3' with the C allele in bold. The
rs17373080 G allele oligo is 5'-GCTAAAGCCAGAA AG C
GCGGGG-3' with G allele in bold. 5.0 μg of the respective
forward and reverse oligos were annealed in 20 mM Tris-
HCl pH 7.8; 2 mM MgCl2; 50 mM NaCl by heating to
95°C for 5 min and slow cooling by 1.5°C/min for 47
cycles. Oligonucleotide probes were labeled by mixing 0.2
μg annealed oligo with 250 μM non-radioactive dATP,
dGTP, dTTP respectively, 1× Klenow buffer, 20 μCi 32P-
labeled dCTP (Amersham Pharmacia) and 1 Unit Klenow
polymerase. Samples were incubated for 20 min at room
temperature. Reactions were stopped by adding 0.5 M
EDTA. Probes were purified using G-25 Nick Columns
(Amersham Pharmacia) and the efficiency of labeling
determined using the 1214 Rackbeta liquid scintillation
counter (LKB Wallac). For binding reactions, 5 μl of MIN6
whole cell extracts were incubated with 4 × 104 cpm of
radiolabeled oligonucleotide in binding buffer (4 μg BSA,
2 μg poly dI-dC, 12 mM HEPES (pH 7.9), 12% glycerol,
0.12 mM EDTA, 0.9 mM MgCl2, 0.6 mM dithiothreitol,
0.6 mM phenylmethylsulfonyl fluoride). Binding reac-
tions were incubated for 20 min at RT, electrophoresed at
150 V for 3 h in 6% polyacrylamide gels at 4°C, dried and
finally analyzed by autoradiography. In competition
assays, the unlabeled competitor was added prior to the
nuclear extracts.
Statistical analyses
The Finetti software and Pearson's Chi2 (d.f. = 1) were
used to compare allele and genotype frequencies between
cases and controls and to calculate odds ratios (OR) [33].
The genetic models analyzed by the Finetti software were
defined as homozygous/recessive: (Case_11*Control_22)
/(Case_22*Control_11) and allele positivity/dominant:
((Case_12+Case_11)*Control_22)/(Case_22* (Control_
12+Control_11)). To take into account the impact of gen-
der on susceptibility to T2D, we used logistic regression
with genotype and sex as independent variables. Haplov-
iew was used to calculate LD between SNPs (D' and r2),
estimate haplotypes, and to test for association between
haplotypes and T2D [32]. The program Thesias was used
to test two-by-two sliding window SNPs haplotypes [34].
This program determines both the haplotype frequency
and its effect on the phenotype through an estimation-
maximisation algorithm. In this analysis, we also consid-
ered gender as a covariate.
ANCOVA with SNP genotypes and gender as main effects
and age, and when appropriate BMI, as simple regressor
was used to analyze differences in HOMAIR, fasting
plasma glucose, serum insulin, and BMI between LXR
genotypes in the non-diabetic population-based cohorts,
SDPP and normoglycemic non-obese samples from the
D.E.S.I.R. respectively. The analyses were repeated in joint
analyses of both cohorts including cohorts as an addi-
tional main effect. 2-h plasma glucose was available and
analyzed as above in the Swedish cohort only. Quantita-
tive phenotypes were normalized by natural logarithm
transformation before analysis to become normally dis-
A. Schematic view of the reporter gene construct driven by  the endogenous -244/+1163 LXRB gene region Figure 3
A. Schematic view of the reporter gene construct 
driven by the endogenous -244/+1163 LXRB gene 
region. The black dot indicates rs17373080. B. Basal activi-
ties of the -244/+1163 rs17373080 G allele and C allele 
reporter constructs. Using in vitro mutagenesis with the G 
allele construct as a template a new C allele construct was 
generated. The results presented are mean differences of 
more than 20 independent transfection experiments. The 
activities of the G allele in each cell line analyzed were set to 
100% ± SEM. * P < 0.05 by Student's t test.
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A. A putative NF1 binding site in the promoter region of the LXRB gene as suggested by TESS (underlined) [36] Figure 4
A. A putative NF1 binding site in the promoter region of the LXRB gene as suggested by TESS (underlined) 
[36]. The rs17373080 SNP is indicated in bold. B. EMSA with MIN6 whole cell extracts (WCE) and labelled oligonucleotides 
with the rs17373080 C and G variants, respectively. Lane 1: Free oligo C, 2: Oligo C + MIN6 WCE, 3–5: Oligo C + MIN6 
WCE + increasing amounts of unlabeled NF1 consensus oligonucleotide, 6: Empty 7: Free oligo G, 8: Oligo G + MIN6 WCE, 
9–11: Oligo G + MIN6 WCE + increasing amounts of unlabeled NF1 consensus oligonucleotide. C. EMSA with rs17373080 
SNP oligo C and MIN6 whole cell extract or in vitro translated (IVT) NF1. Lane 1: Free oligo C, 2: Oligo C + MIN6 whole cell 
extract, 3: Oligo C + MIN6 whole cell extract + 250× unlabeled NF1 consensus oligonucleotide, 4: Oligo C + Empty IVT 
expression vector (vehicle) and 5–7: Oligo C + IVT NF1A1, NF1B and NF1X, respectively. The arrows indicate the positions 
of the NF1 interactions.
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tributed. In the transient transfections functional studies
the student's t-test was applied.
Results
Analysis of association between LXR gene SNPs and T2D
We first analyzed LXRs SNPs for association with T2D in
the French case-control cohort. Altogether we genotyped
five LXRA SNPs and three LXRB SNPs. All SNPs had a call
rate of ≥ 93% and were in HWE in the French cohort
(Table 1). We analyzed LXR SNPs for association with
T2D under different genetic models. No SNP allele associ-
ated to T2D (Table 1). However, genotype at the LXRB
promoter SNPs rs35463555 and rs17373080 associated
nominally to T2D assuming a dominant T2D-predispos-
ing common allele, P value 0.047 and 0.026 respectively
(Table 2). This was due to an increased risk of T2D among
heterozygous and protection against T2D among subjects
homozygous for the rare allele (Table 1). None of ana-
lyzed SNPs showed significant association with T2D when
taking into account the gender effect. SNPs within LXRA
and LXRB were in strong LD and together built one hap-
loblock for the respective genes (Figure 2). No LXRA and
no LXRB haplotype associated with T2D (Table 3). Fur-
thermore, no two-by-two sliding window SNPs haplo-
types associated with T2D (results not shown).
Analysis of association between LXR SNPs and 
quantitative phenotypes reflecting glucose homeostasis
We next analyzed LXR gene SNPs for impact on quantita-
tive phenotypes related to glucose homeostasis in non-
diabetic subjects. For this purpose, we analyzed the nor-
moglycemic non-obese population-based samples
selected from the French D.E.S.I.R. cohort and the Swed-
ish SDPP cohort. Phenotypes of these cohorts are shown
in Table 4. In the Swedish cohort an oral glucose tolerance
test was performed and the analyzed cohort included 320
subjects with IGT. Genotyping result for the D.E.S.I.R.
samples is included in the controls in Table 1. Genotype
results for SDPP are shown in Table 5. All SNPs had call
rates ≥ 96%. All SNPs were in HWE. Allele frequencies for
LXRB  SNPs were almost identical in the Swedish and
French cohorts whereas allele frequencies for LXRA SNPs
differed 4–10% between the populations. LXR SNPs had
no impact on fasting plasma glucose or serum insulin,
insulin resistance measured as HOMAIR or BMI in either
the D.E.S.I.R. or the SDPP cohort, nor in the joint analysis
of both cohorts (results not shown). Nor did LXR SNPs
associate to the response to an OGTT in SDPP (results not
shown).
Functional analysis of the LXRB rs17373080 SNP
The C allele of rs17373080 associates with higher transcription 
activity in vitro
We have previously determined the transcription start site
of the human LXRB gene promoter [35]. The LXRB SNP
rs17373080 is located in the proximal promoter close to
the transcription start site and could potentially have an
impact on the transcription potential of the LXRB gene
promoter. Hence we performed functional studies investi-
gating this SNP. The -244/+1163 gene region including
the rs17373080 with either the C or the G allele was PCR
cloned in front of the luciferase gene reporter (Figure 3A).
Otherwise the promoters were identical. The activities of
the two different alleles were analyzed in transient trans-
fection assays in three different cell lines. There was a sig-
Transient co-transfections with the -244/+1163 C (A) or G  (B) reporter constructs and members of the NF1 family of  transcription factors in three different cell lines as indicated Figure 5
Transient co-transfections with the -244/+1163 C (A) 
or G (B) reporter constructs and members of the 
NF1 family of transcription factors in three different 
cell lines as indicated. Each transient transfection was 
made in triplicates and the results presented are mean differ-
ences of three independent experiments. C or G alleles with 
co-transfection of empty pCH-vector were set as controls. 
Both C and G allele controls are set to 100% and the effect 
of NF1 expression compared to either the C-Control (A) or 
G-Control (B). * indicated significant difference (P < 0.05) ± 
SEM.
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nificantly higher basal activity for the C allele in all three
cell lines investigated (Figure 3B) indicating that the C
allele is able to maintain a higher basal transcription of
the LXRB gene.
A functional NF1 binding site overlaps rs17373080
A theoretical search for transcription factor binding sites
using the transcription element search system (TESS) sug-
gested a binding site for the NF1 transcription family
members overlapping the rs17373080 position (Figure
4A) [36]. The different alleles were tested for interaction
with NF1 using direct DNA binding and transactivation
assays. The DNA-mobility shift assay indicated equal
binding of components in whole cell extracts to oligonu-
cleotides corresponding to the C and G alleles, respec-
tively (Figure 4B, lanes 2 and 8) and the DNA-protein
interaction was competed away by increasing amounts of
an unlabelled NF1 consensus binding site (lanes 3–5 and
9–11). NF1A1, NF1B and NF1X produced by in vitro tran-
scription/translation gave protein-DNA complexes of the
same size as that produced by whole cell extracts (results
not shown). Different NF1 family members (NF1A1,
NF1B, NF1C and NF1X) showed different transactivation
capacity on the LXRB gene promoter (Figure 5). However,
no difference in induced transactivation activity of the
NF1s was observed between the G (Figure 5A) and C (Fig-
ure 5B) promoter alleles.
Discussion
We have analyzed common genetic variation in LXRA and
LXRB for association with T2D in one French cohort and
for association with quantitative measures of glucose
homeostasis in two non-diabetic population-based sam-
ples from France and Sweden. Genotype at the LXRB pro-
moter SNPs rs17373080 and rs35463555 nominally
associates to T2D. rs17373080, which regulates transcrip-
tion in vitro, may directly affect the risk of developing T2D
whereas the association between T2D and rs35463555,
which is located in a repeat, could be due to strong LD
with 17373080. No LXRA SNPs associate to the investi-
gated phenotypes.
We have previously reported that LXRB SNPs associate
with obesity in a Swedish cohort [rs35463555 (previously
known as LB44732G>A), rs2695121, and marginally,
rs17373080 (P value 0.06)] [11]. The genotype at
rs35463555 and rs17373080 predisposing to obesity in
the previous study was found to also associate to T2D in
this study. The association between rs35463555,
rs17373080 and T2D reported here would become non-
significant following Bonferroni-correction for analysis of
several LXR SNPs and phenotypes. However, since our
results are confirmatory in nature, that is the rs35463555
and, marginally, rs17373080 SNPs have previously been
associated with another metabolic phenotype, namely
obesity, we think it is too stringent to perform Bonferroni
correction. Similarly, since analysed phenotypes are
dependent, Bonferroni correction may be too stringent.
On the other hand, it is important to note that observed
association P values for rs35463555 and rs17373080
(0.047 and 0.026) are weak and would become non-sig-
nificant following adjustment for just two independent
analyses. We did not observe any association between
LXRB SNPs and BMI in this study. This may be due to phe-
notypic differences between cohorts. The population-
based cohorts D.E.S.I.R. and SDPP that we analyzed here
contain markedly less obese people than the previous
Swedish study. Together, previous and present results sup-
port that LXRB promoter genotype regulates susceptibility
to adiposity as well as T2D. However, replications of these
associations in additional large cohorts are necessary
before establishing an association between LXRB geno-
type, obesity and T2D. Published genome wide associa-
tion studies of T2D have not reported association with
LXR genes [16-24,37-39]. However, it is uncertain to what
extent these studies cover the rather small LXRA and LXRB
genes since the full datasets are unavailable. In the French
cohort, gender distribution was the opposite in T2D cases
versus controls. The main concern with different gender
distribution in cases and controls is reduced power to
identify T2D genes due to gender impact on T2D suscep-
tibility and potential gene-gender interaction.
An LXRB promoter SNP could contribute to development
of T2D by altering mRNA levels of LXRB in one or more
of the organs regulating glucose homeostasis; LXRB  is
expressed in pancreas, liver, muscle, as well as adipose tis-
sue [40]. It has recently been reported that LXRB is the
main LXR paralogue in pancreatic beta-cells, that activated
LXR induces insulin secretion from beta-cells and that
mice lacking the Lxrb gene have less glucose stimulated
insulin secretion [9]. The T2D-associated LXRB promoter
SNP rs35463555 is located in a large repeat region of
~2500 base pairs and is therefore difficult to clone and
study functionally. An in silico search using TESS revealed
no binding sites for human transcription regulators cover-
ing rs35463555 [36]. Therefore, we did not perform any
functional studies of this SNP. As for the proximal LXRB
promoter SNP rs17373080, according to our results the
GG genotype protected against T2D whereas the G allele
showed reduced reporter gene activity, which suggests that
the G allele is associated with lower LXRB mRNA levels.
Thus, these results are contrary to what one would expect
based on the results in the Lxrb knock-out mice. However,
rs17373080 may regulate overall glucose homeostasis
through other mechanisms and in other organs in
humans.
We observed that the rs17373080 SNP overlapped an NF1
site. The NF1 site was functional in recruiting NF1. How-BMC Medical Genetics 2009, 10:27 http://www.biomedcentral.com/1471-2350/10/27
Page 12 of 13
(page number not for citation purposes)
ever, we did not observe any differences between the G
and C alleles in DNA-binding and transactivation of a
reporter gene by NF1 family members. It cannot be
excluded that rs17373080 overlaps additional transcrip-
tion factor binding sites and that the binding and/or activ-
ity of these sites is affected by the various rs17373080
alleles. It might also be that the differences between the C
and G alleles with regard to transcription factor-induced
transcription activity are too subtle to be detected with
existing methods. However, our results indicate that the
transcriptional activity of NF1 could be tissue or cell spe-
cific as similar results were observed in Cos7 and MIN6
cells, but not in HuH7 cells. Speculatively, these results
could suggest that the relevance of the SNP rs17373080 in
developing T2D could be tissue specific and further stud-
ies should be focusing on the role of LXRB in these cell
types where NF1 was shown to affect the transcription rate
of the LXRB gene.
There was no association between SNPs covering the com-
mon variation in LXRA and susceptibility to T2D or levels
of plasma glucose, serum insulin, and insulin resistance
measured as HOMAIR. According to power calculations
our cohorts were large enough to detect also a modest
impact of LXRA on these phenotypes and it is therefore
unlikely that this gene directly regulates glucose homeos-
tasis. We did not have access to blood lipids in the SDPP
cohort. This prohibited us from determining which sub-
jects fulfilled the criteria for the metabolic syndrome and
from analysing LXR genotypes for influence on this phe-
notype. We hypothesize, based on previously reported
association of LXRA alleles with the metabolic syndrome
and HDL levels, together with the lack of association with
T2D and measures of glucose homeostasis reported here,
that the impact of LXRA on susceptibility to the metabolic
syndrome is mediated via an impact on lipid turnover
rather than glucose homeostasis [12].
Conclusion
The common LXRB  promoter SNPs rs35463555 and
rs17373080 may regulate susceptibility to T2D, whereas
common genetic variation in LXRA is unlikely to affect the
risk of developing T2D or quantitative phenotypes related
to glucose homeostasis. The association between LXRB
rs35463555 and rs17373080 and T2D needs to be inves-
tigated in additional large cohorts.
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